Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 3/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033084 | 0.88 | SLC13A5 (0.48) | RXRARXRBSLC13A5GGPS1DGAT1 | |
| SCHEMBL3484666 | 0.87 | SLC13A5 (0.45) | RXRARXRBCYP4F2CYP4A11SLC13A5 | |
| SCHEMBL3485054 | 0.86 | FFAR4 (0.47) | RXRARXRBGGPS1DGAT1FFAR1 | |
| SCHEMBL4033371 | 0.77 | PPARA (0.54) | RXRARXRBSLC13A5FFAR1 | |
| SCHEMBL4035971 | 0.74 | MAP4K4 (0.53) | RXRARXRBSLC13A5 | |
| SCHEMBL3484417 | 0.74 | PPARA (0.40) | RXRARXRBSLC13A5MAOBMME | |
| SCHEMBL30516648 | 0.74 | MAOB (0.66) | CYP4F2CYP4A11SLC13A5MAOBHSD17B2 | |
| SCHEMBL5367643 | 0.74 | SSTR4 (0.51) | DGAT1 | |
| SCHEMBL10468492 | 0.74 | MAOB (0.66) | CYP4F2CYP4A11SLC13A5MAOBHSD17B2 | |
| SCHEMBL3483937 | 0.73 | PPARA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | IPO5, PPIP5K2, IPO4 | RXRA 3134/4885RXRB 3035/4885CYP4F2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.